What Are Wall Street Analysts' Target Price for Waters Corporation Stock?
Waters Corporation (WAT) has underperformed the broader market and the healthcare sector ETF over the past year and year-to-date. Despite beating Q4 earnings estimates, its stock dropped significantly. Analysts currently have a "Moderate Buy" consensus rating with a mean price target suggesting a 21.2% upside.
Waters introduces next-generation Microflow LC Columns with MaxPeak premier technology
Waters Corporation has launched new 1 mm I.D. liquid chromatography (LC) columns featuring MaxPeak™ Premier Technology for its ACQUITY™, BioResolve™, and GTxResolve™ Column brands. These microflow columns enhance sensitivity and minimize solvent and sample waste, delivering high-quality results for bioanalysis, pharmaceutical discovery, and metabolomics by reducing nonspecific adsorption and improving analyte recovery. The technology provides sharper peaks and improved reproducibility, which is critical for limited sample availability and challenging analyte recovery, while also reducing solvent use for environmental benefits.
$19.8 Billion Cell and Gene Therapy Tools & Reagents Market Outlook, 2030 Featuring Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, Sartorius and More
The global market for cell and gene therapy tools and reagents is projected to reach $19.8 billion by 2030, growing at a CAGR of 10.6% from $12 billion in 2025. This growth is driven by increasing clinical and commercial activities in cell and gene therapies (CGTs), significant R&D investments, and regulatory approvals for novel CGTs. The market report provides comprehensive insights into segmentation by product type, application, and end-user, profiling key players such as Thermo Fisher Scientific, Cytiva (Danaher), Merck, Miltenyi Biotec, and Sartorius.
1 S&P 500 Stock on Our Buy List and 2 We Ignore
StockStory identifies Jack Henry (JKHY) as a top S&P 500 buy due to its strong revenue growth and market-beating return on equity. Conversely, the analysis recommends avoiding Waters Corporation (WAT) and Morgan Stanley (MS) citing shrinking returns on capital and lagging earnings per share respectively.
Waters Corp (WAT) Trading Down 3.86% on Feb 17
Waters Corp (WAT) saw its shares decline by 3.86% on February 17, trading at $310.88. This places the stock 24.94% below its 52-week high, with analysts setting an average target price of $407.35, suggesting a 31.03% upside. GuruFocus estimates the fair value at $711.15, implying an even greater upside of 128.76%.
Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage – Company Announcement - FT.com
Waters Corporation has launched new 1 mm I.D. microflow LC columns with MaxPeak Premier Technology, significantly improving sensitivity and minimizing solvent and sample waste in critical applications like bioanalysis and pharmaceutical development. These columns offer up to twice the sensitivity of stainless steel alternatives and use substantially less sample and solvent, addressing the needs of high-throughput laboratories and supporting sustainability goals. The technology reduces nonspecific adsorption, enhances recovery, and provides reproducible performance, benefiting workflows for challenging analyte recovery and enabling more efficient research.
Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
Waters Corporation has launched new 1 mm I.D. liquid chromatography (LC) columns with MaxPeak Premier Technology for its ACQUITY™, BioResolve™, and GTxResolve™ Column brands. These columns offer up to two times higher sensitivity, use 75% less sample, and reduce solvent consumption by up to four times compared to traditional columns, benefiting high-throughput bioseparations, DMPK, and 'omics applications. This innovation aims to accelerate and simplify the development of life-changing therapies by improving sample recovery and data quality, particularly in areas with limited sample availability.
Gas Chromatography Systems Market to Reach US$7.20 Billion
The global Gas Chromatography Systems Market is projected to reach US$7.20 billion by 2032, growing at an 8.8% CAGR from 2025 to 2032, up from US$3,668.75 million in 2024. This growth is driven by increasing demand for advanced analytical instrumentation in various sectors like environmental analysis, pharmaceuticals, and food safety, with North America leading the market. Key players like Thermo Fisher Scientific, Agilent Technologies, and Shimadzu Corporation are advancing the market through technological innovations in detector sensitivity, automation, AI integration, and the development of portable systems.
Waters Introduces Next-Generation Microflow LC Columns with MaxPeak Premier Technology, Delivering Higher Sensitivity with Lower Sample and Solvent Usage
Waters Corporation has launched new 1 mm I.D. microflow liquid chromatography (LC) columns featuring MaxPeak Premier Technology, designed to enhance sensitivity and reduce sample and solvent usage. These columns aim to improve analytical performance in various applications like bioanalysis, pharmaceutical development, and 'omics, especially where sample availability is limited. The technology minimizes nonspecific adsorption, leading to higher recovery, sharper peaks, and more reproducible results, while also supporting environmental goals by reducing solvent consumption.
New Waters microflow columns use 75% less sample in drug R&D
Waters Corporation has launched new 1 mm I.D. microflow LC columns with MaxPeak Premier Technology, designed for ACQUITY, BioResolve, and GTxResolve brands. These columns offer up to twice the sensitivity, use 75% less sample, and reduce solvent consumption by up to four times compared to 2.1 mm I.D. columns. This innovation aims to address challenges in bioanalysis, pharmaceutical development, and 'omics applications by improving recovery for various molecules while conserving precious resources.
5 Must-Read Analyst Questions From BD's Q4 Earnings Call
BD (Becton, Dickinson and Company) reported strong Q4 results with revenue and EPS exceeding analyst estimates, driven by growth in biologic drug delivery, advanced tissue regeneration, and pharmacy automation. Despite challenges from China and vaccine-related pressures, the company maintained focus on investments in growth platforms and productivity. Analyst questions highlighted concerns about future guidance, portfolio changes, and the long-term outlook for GLP-1 devices, with management providing clarifying responses.
Waters Corporation (NYSE:WAT) Receives Average Recommendation of "Moderate Buy" from Brokerages
Waters Corporation (NYSE:WAT) has received an average rating of "Moderate Buy" from twenty-one brokerages, with an average 12-month target price of $397.68. This follows a Q4 earnings beat and strong FY-2026 guidance, attracting significant institutional investment, with Marshall Wace LLP notably increasing its stake. Despite a recent price target cut from Bank of America, the overall sentiment remains positive due to strong fundamentals and analyst coverage.
Rhumbline Advisers Buys 7,636 Shares of Waters Corporation $WAT
Rhumbline Advisers increased its stake in Waters Corporation by 6.1%, acquiring an additional 7,636 shares, bringing its total ownership to 132,795 shares valued at $39.8 million. This move comes as Waters Corporation reported strong Q4 earnings, beating analyst expectations, and issued positive guidance for fiscal year 2026. The stock currently holds a "Moderate Buy" consensus rating from analysts, with a target price of $397.68.
Is First Trust Multi Cap Growth AlphaDEX ETF (FAD) a Strong ETF Right Now?
The First Trust Multi Cap Growth AlphaDEX ETF (FAD) provides broad exposure to the All Cap Growth category, using a smart beta strategy based on fundamental characteristics. The ETF has gained approximately 10.63% this year and 18.30% over the past year, with a medium risk profile. Investors should compare it with lower-cost alternatives and conduct thorough research to assess analyst target price validity and inherent risks.
Down 19.0% in 4 Weeks, Here's Why Waters (WAT) Looks Ripe for a Turnaround
Waters (WAT) shares have fallen 19% in the last four weeks but appear poised for a turnaround. The stock is in oversold territory with an RSI of 23.31, suggesting potential for a rebound. Additionally, analysts have collectively raised earnings estimates for the current year by 1.1% over the past 30 days, and WAT currently holds a Zacks Rank #2 (Buy), indicating further potential for appreciation.
Citi Raises Becton Dickinson (BDX) PT to $198 after Life Sciences Sale Update
Citi analyst Joanne Wuensch increased her price target for Becton, Dickinson and Company (NYSE: BDX) to $198 from $185.70, maintaining a Buy rating. This adjustment follows an update to Citi's financial model to reflect the sale of BDX's Life Sciences business. BDX's fiscal Q1 2026 earnings exceeded expectations with $5.3 billion in revenue, and the company plans a $4 billion cash distribution from the Life Sciences sale, allocating $2 billion to share repurchases and $2 billion to debt reduction.
Krilogy Financial LLC Takes Position in Becton, Dickinson and Company $BDX
Krilogy Financial LLC has initiated a new position in Becton, Dickinson and Company (BDX) by purchasing 8,332 shares valued at approximately $1.47 million during the third quarter. Institutional investors now collectively own nearly 87% of the company's stock. This move comes as BDX recently beat Q4 earnings expectations, provided FY2026 guidance, authorized a $10 million share buyback, and completed a spin-off of its Biosciences & Diagnostics business to become a pure-play MedTech company, a shift that has garnered mixed analyst reactions.
Citi Raises Becton Dickinson (BDX) PT to $198 after Life Sciences Sale Update
Citi analyst Joanne Wuensch increased her price target for Becton, Dickinson and Company (NYSE: BDX) to $198 from $185.70, maintaining a Buy rating after the firm updated its financial model for the sale of the Life Sciences business. BDX's Q1 2026 results exceeded expectations, with revenue reaching $5.3 billion and adjusted EPS at $2.91. The company plans to close the Life Sciences unit sale, generating $4 billion for share repurchases and debt reduction, aligning with its "Excellence Unleashed" agenda.
Waters (WAT) Q4 2025 Earnings Call Transcript
Waters (WAT) reported strong Q4 and full-year 2025 results, with Q4 sales of $932 million and adjusted EPS of $4.53. The company provided 2026 guidance, targeting combined revenue of $6.41 billion to $6.46 billion and adjusted EPS of $14.30 to $14.50, reflecting significant growth and accretion from its recent acquisition of BD Biosciences and Diagnostic Solutions. Waters highlighted strategic reorganization into four divisions and detailed substantial cost and revenue synergies expected from the integration.
Is Waters a Better Buy Than Thermo Fisher Scientific?
This article analyzes whether Waters (WAT) is a better investment than Thermo Fisher Scientific (TMO). It suggests that WAT offers superior revenue growth, better profitability, and a relatively lower valuation compared to TMO, despite TMO's recent stock decline. The comparison is supported by side-by-side financial metrics and historical market performance data for both companies.
Waters slips despite Q4 beat as outlook disappoints
The article reports that Waters Corporation's stock slipped despite beating Q4 expectations, likely due to a disappointing outlook. This suggests investor concern over future performance despite recent positive results.
TD Cowen Raises Becton, Dickinson and Company (NYSE:BDX) Price Target to $189.00
TD Cowen has increased its price target for Becton, Dickinson and Company (NYSE:BDX) to $189 from $183, while reiterating a "hold" rating. This adjustment follows Becton, Dickinson beating its Q1 earnings and revenue estimates, reporting $2.91 EPS against an expected $2.81, and revenues of $5.25 billion. The company also announced a modest share buyback of $10 million and tender offers to repurchase up to $1.6 billion in debt, reflecting active capital management.
Becton, Dickinson and Company (NYSE:BDX) Given Average Recommendation of "Hold" by Brokerages
Becton, Dickinson and Company (NYSE:BDX) has received a "Hold" consensus recommendation from fourteen brokerages, with nine analysts rating it a "hold" and five a "buy." The average one-year price target is $196.00, though targets vary significantly. The company recently completed a spin-off, reported strong Q1 results, and initiated debt tender offers and a share buyback program.
Candriam S.C.A. Has $2.87 Million Position in Becton, Dickinson and Company $BDX
Candriam S.C.A. decreased its stake in Becton, Dickinson and Company (BDX) by 33.7% in Q3, now holding 15,305 shares worth approximately $2.865 million. BDX recently completed a spin-off of its biosciences & diagnostics unit, becoming a pure-play medical technology company and reporting strong Q1 FY2026 sales and EPS. Despite mixed analyst sentiment, with an average "Hold" rating and $196 price target, the company declared a quarterly dividend of $1.05 and authorized a $10 million share repurchase plan.
BD Merges Biosciences & Diagnostics Business With Waters
Becton, Dickinson and Company (BD) completed the spin-off of its Biosciences & Diagnostic business, merging it with Waters Corporation, a move that aligns with BD's 2025 strategy to become a more focused MedTech organization. BD shareholders received Waters common stock, and BD gained $4 billion in proceeds, which it plans to use for share repurchases and debt reduction. The company aims to capitalize on trends like connected and AI-enabled medical technologies, strengthening its strategic focus and growth prospects.
Waters (WAT) Sees Price Target Downgrade by Wells Fargo | WAT St
Wells Fargo analyst Brandon Couillard has downgraded Waters (WAT) price target from $415 to $355, while maintaining an "Equal-Weight" rating. This follows similar price target reductions by B of A Securities and UBS, though Guggenheim and HSBC initiated or reiterated "Buy" ratings with higher price targets. Waters is a manufacturer of liquid chromatography, mass spectrometry, and thermal analysis tools, with plans to merge with BD's life science and diagnostics business.
Agilent presents Boehringer Ingelheim with inaugural 2025 instrument Trade-in Impact Award
Agilent Technologies awarded Boehringer Ingelheim the inaugural 2025 Instrument Trade-in Impact Award for its commitment to sustainability by recycling older instruments. Boehringer Ingelheim is lauded for its significant contribution to minimizing landfill waste and reducing raw material consumption through Agilent's trade-in program. This initiative aligns with both companies' dedication to sustainable practices in scientific instrumentation.
Waters Corporation $WAT Stock Holdings Decreased by Madison Asset Management LLC
Madison Asset Management LLC reduced its stake in Waters Corporation (NYSE:WAT) by 1.5% in the third quarter, while institutional ownership remains high at 94.01%. Despite beating Q4 earnings estimates, Waters experienced share weakness due to Q1 2026 guidance falling below street expectations. Analysts hold a "Moderate Buy" rating, with an average target price of $400.84, although some firms adjusted targets due to integration risks with BD’s Biosciences & Diagnostic Solutions.
Waters Corp. stock price target lowered to $373 at TD Cowen
TD Cowen has lowered its price target for Waters Corp. (NYSE:WAT) to $373 from $400, maintaining a Hold rating despite the stock's recent 14% decline after its fourth-quarter earnings report. This adjustment follows a significant stock hit and coincides with Becton Dickinson’s weak performance. Waters management remains confident in its deal with BDX, and while valuation appears more attractive, confidence in BDX's recovery is crucial for Waters' stock.
Gas Chromatography Detector Market Is Going to Boom |• Agilent Technologies • Thermo Fisher Scientific
Worldwide Market Reports has published a comprehensive study on the "Gas Chromatography Detector Market Size and Forecast 2026-2033," analyzing growth trends, drivers, and challenges. The report provides detailed insights into market segmentation by types and applications, regional performance, and profiles key players like Agilent Technologies and Thermo Fisher Scientific. It also utilizes analytical tools such as SWOT and Porter's Five Forces to assess the competitive landscape.
Quest Diagnostics (DGX): Navigating the New Frontier of Advanced Diagnostics and AI Efficiency
Quest Diagnostics (DGX) is transforming its business by aggressively pivoting towards advanced diagnostics and AI-driven efficiency, leading to a fresh 52-week high for its shares. This shift, combined with a strong fourth-quarter earnings report and a legislative reprieve on Medicare reimbursement rates, positions Quest as a critical "lab engine" in the evolving healthcare landscape, particularly in precision medicine. The company is focusing on innovations like AD-Detect for Alzheimer's and Haystack MRD for cancer monitoring, while also streamlining operations through "Project Nova" and navigating competitive and regulatory challenges.
Pure-Play Pivot: A Deep Dive into Becton Dickinson (BDX) Following the Waters Spin-Off and 2026 Guidance Reset
Becton, Dickinson and Company (BDX) has undergone a significant transformation, spinning off its Biosciences and Diagnostic Solutions business into a merger with Waters Corporation to become a "Pure-Play MedTech" company. This strategic pivot aims to unlock long-term value, but it has led to a simultaneous downward revision of full-year earnings guidance for 2026, causing stock volatility. Despite this "transition year" reality, the company's balance sheet is bolstered by the Waters deal, and management plans to focus on debt reduction and an aggressive share repurchase program.
Pure-Play Pivot: A Deep Dive into Becton Dickinson (BDX) Following the Waters Spin-Off and 2026 Guidance Reset
Becton Dickinson (BDX) has completed the spin-off of its Biosciences and Diagnostic Solutions business, merging it with Waters Corporation, to become a "Pure-Play MedTech" company. This transformation comes with a revised, lower full-year earnings guidance for 2026, leading to market volatility. Despite short-term investor concerns, the company aims to unlock long-term value through its focused strategy, debt reduction, share repurchases, and positioning in high-growth areas like GLP-1 related solutions.
Nuveen Preferred & Income Opportunities Fund (NYSE:JPC) Stock Price Passes Above Fifty Day Moving Average – Time to Sell?
Shares of Nuveen Preferred & Income Opportunities Fund (NYSE:JPC) have risen above their fifty-day moving average, trading as high as $8.27. The company recently declared a monthly dividend of $0.0625 per share, creating an annualized yield of 9.1%. Institutional investors have also adjusted their holdings, with several firms increasing their stakes in JPC during the fourth quarter.
Waters Corporation (NYSE:WAT) Q4 2025 Earnings Call Transcript
Waters Corporation reported strong Q4 2025 results, exceeding earnings expectations with an EPS of $4.53. The company achieved high single-digit revenue growth and double-digit adjusted EPS growth, driven by pharma and industrial end markets and recurring revenue. Waters also completed the acquisition of BD’s Biosciences and Diagnostic Solutions business, outlining a new operating structure and expecting significant synergies and an industry-leading growth outlook for 2026 for the combined entity.
Waters Corp. stock price target lowered to $373 at TD Cowen
TD Cowen has lowered its price target for Waters Corp. (NYSE:WAT) to $373 from $400, while maintaining a Hold rating. This adjustment follows a 14% stock decline after Waters Corp.'s fourth-quarter earnings report and challenges faced by Becton Dickinson, a key partner. Despite the lower target, TD Cowen believes Waters' valuation is more attractive, although a recovery for Becton Dickinson is crucial for future stock performance.
Waters Corp. price target lowered to $370 from $395 at UBS
UBS has lowered its price target for Waters Corp. (NYSE:WAT) to $370 from $395, while maintaining a Neutral rating, due to group multiple contraction and concerns over the integration of Becton Dickinson's Life Sciences businesses. Although Waters' Q4 2025 results and FY 2026 guidance met expectations, the firm noted a more pronounced deterioration than expected in the acquired Becton Dickinson business. Other analysts like TD Cowen, Barclays, and Evercore ISI have also adjusted their ratings and price targets for Waters Corp., reflecting varied outlooks on the company's future performance.
What's Going On With Becton Dickinson Stock Tuesday?
Becton Dickinson (NYSE: BDX) reported first-quarter 2026 adjusted earnings above consensus but lowered its fiscal 2026 adjusted earnings guidance, making it a "transition year" according to RBC Capital Markets. Several analysts, including RBC, Wells Fargo, and Piper Sandler, consequently cut their price targets for BDX, while Citigroup also lowered its target slightly. Becton Dickinson's stock was down significantly following these developments.
Waters Corp. price target lowered to $370 from $395 at UBS
UBS has lowered its price target for Waters Corp. (NYSE:WAT) to $370 from $395, while maintaining a Neutral rating. This adjustment reflects group multiple contraction and concerns over the integration of Becton Dickinson’s Life Sciences businesses, despite Waters Corp. meeting fourth-quarter expectations. The company also provided a first-quarter profit forecast that trailed analyst estimates, further contributing to a mixed outlook from various financial analysts.
Becton Dickinson Refocuses On Medtech After Waters Spin Off And Buyback
Becton Dickinson (NYSE:BDX) has revamped its business by spinning off its Biosciences and Diagnostic Solutions units into a merger with Waters, aiming for a more focused medtech operation. This restructuring is accompanied by strong Q1 results, a $2 billion share repurchase program, and debt reduction plans. The company's stock shows recent positive momentum, with management emphasizing a streamlined core business and clear capital allocation priorities for investors.
Becton Dickinson Refocuses On Medtech After Waters Spin Off And Buyback
Becton Dickinson (NYSE:BDX) has completed a $17.5 billion spin-off and merger of its Biosciences and Diagnostic Solutions businesses with Waters, reshaping itself as a focused medtech company. This strategic move is accompanied by a new capital allocation plan, including a $2 billion share repurchase program and debt reduction, following strong Q1 results. The company aims to streamline its operations and improve investor confidence after negative returns over the past few years.
Citigroup Has Lowered Expectations for Becton, Dickinson and Company (NYSE:BDX) Stock Price
Citigroup has trimmed its price target for Becton, Dickinson and Company (NYSE:BDX) to $232 from $233, while maintaining a "buy" rating, implying a 36% upside. Despite the company beating Q1 EPS and revenue estimates, management lowered its FY26 profit guidance due to the sale/spin-off of its Biosciences & Diagnostic Solutions unit, causing shares to fall approximately 18% to $170. Analysts now hold a consensus "Hold" rating with an average target price of $198.50 for BDX.
Waters Corporation (WAT): Guggenheim Reiterates 'Buy' Rating with Unchanged Price Target | WAT Stock News
Guggenheim has reiterated its 'Buy' rating for Waters Corporation (WAT) and maintained a price target of $440, signaling continued confidence in the company's stock. This follows other recent analyst ratings, including a 'Buy' from HSBC and an 'Outperform' from William Blair. Wall Street analysts forecast an average target price of $417.76 for WAT, implying a 27.31% upside from its current price, and GuruFocus estimates a fair value of $372.94, suggesting a 13.65% upside.
Waters Corp. price target lowered to $370 from $395 at UBS
UBS has lowered its price target for Waters Corp. (NYSE:WAT) to $370 from $395, while maintaining a Neutral rating due to group multiple contraction and challenges with integrating Becton Dickinson's Life Sciences business. Despite Waters' Q4 2025 results being in line with expectations, the performance of the acquired Becton Dickinson business was weaker than anticipated. This adjustment comes amidst mixed analyst reactions, with some firms lowering targets and others resuming coverage with "Overweight" ratings.
BD Completes Spin-Off of Biosciences Unit, Merges With Waters
Becton, Dickinson and Company (BD) has completed the spin-off of its Biosciences & Diagnostic Solutions unit, merging it with Waters Corporation in a transaction valued at approximately US$17.5 billion. This deal reshapes BD's portfolio, positioning it as a focused medical technology company, while creating a global leader in life sciences and diagnostics with a combined addressable market of roughly US$40 billion. The transaction also included BD receiving US$4 billion in cash, which it plans to use for share repurchases and debt repayment, marking the final milestone of its 2025 strategy.
Waters (WAT) Gains Barclays' Favor Following Strategic Acquisiti
Barclays has initiated coverage on Waters (WAT) with an Overweight rating and a $400 price target, following Waters' strategic acquisition of Becton Dickinson's Life Sciences Bioprocessing segment. This acquisition is expected to strengthen Waters' market position in medical diagnostics and research. The company exhibits strong financial health with robust revenue growth, high operating margins, and a solid balance sheet, positioning it well for future growth despite sector-specific risks.
Waters Corp. stock price target lowered to $373 at TD Cowen
TD Cowen has lowered its price target for Waters Corp. (NYSE:WAT) to $373 from $400, maintaining a Hold rating despite the stock's recent 14% decline after its Q4 earnings report. The adjustment reflects mixed sentiments among analysts, with some seeing value post-pullback and others expressing concerns over future guidance and the Becton Dickinson deal. Waters' Q4 earnings slightly surpassed expectations, but its Q1 profit forecast fell short of analyst estimates.
Minimal Residual Disease Testing Market Poised for Rapid Growth
The global Minimal Residual Disease (MRD) Testing Market is projected to grow at a CAGR of 12.5% during 2024-2031, driven by advancements in precision oncology. This market focuses on detecting low levels of cancer cells post-treatment, especially in hematologic malignancies, utilizing technologies like PCR, next-generation sequencing, and flow cytometry. Key players such as Adaptive Biotechnologies Corp. and Guardant Health are contributing to innovations and partnerships that enhance diagnostic precision and clinical utility.
BD shares fall by 3% after lowering FY26 profit outlook
Becton Dickinson and Company (BD) saw its share price fall by 3% after trimming its fiscal year 2026 (FY26) profit outlook. This adjustment follows the formal completion of the spin-off of its biosciences & diagnostic solutions business, which merged with Waters in a $17.5bn agreement. Despite the stock drop, BD reported stronger-than-expected Q1 FY2026 results, with profits of $5.25bn, a 1.6% rise from the previous year.
Waters Corporation (WAT) Shares Fall 14.5% Following FY2026 Guidance Despite Q4 Beat
Waters Corporation's shares fell by 14.5% after the company provided a lower-than-expected profit outlook for fiscal year 2026, despite beating fourth-quarter earnings estimates. The guidance reflects a valuation compression due to the recent acquisition of BD’s biosciences unit and anticipates a lower margin profile. The company faces headwinds from cautious corporate spending and weakened demand in China.
